DNLI

Denali Therapeutics Inc.

20.72 USD
-0.01 (-0.05%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Denali Therapeutics Inc. stock is up 1.02% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 June’s closed higher than May. In the last 2 Unusual Options Trades, there were 2 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
16 Apr 13:45 21 Jun, 2024 20.00 PUT 100 424
24 Apr 14:18 21 Jun, 2024 17.50 PUT 100 291

About Denali Therapeutics Inc.

Denali Therapeutics Inc. discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate product candidate. BIIB122/DNL151, a small molecule inhibitor, is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease.